Jazz Pharmaceuticals Announces Second Quarter 2026 Financial Results

EarningsZiihera®Xywav®Positive

AI Analysis

Summary

Jazz Pharmaceuticals reported Q2 2026 financial results with record total revenues of $1.2 billion, up 16% year-over-year, and raised full-year 2026 revenue guidance. The company is prepared to launch Ziihera® in HER2+ first-line gastric esophageal adenocarcinoma immediately following FDA approval, while Xywav® revenues grew 13% YoY with 525 net patient additions.

Financial Highlights

Revenue

$1.2 billion

Guidance

raised 2026 revenue guidance

Importance:5/10

Sentiment:

0.70

earningsrevenue_growthproduct_launchguidance_raisecommercial_execution

Related Companies

$JAZZ

Read the original article

Published by PR Newswire Pharma on August 3, 2026 8:05 PM

Read Original